Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis

Maako Ide, Kentaro Tanaka, Shunya Sunami, Tatsuma Asoh, Takashige Maeyama, Nobuko Tsuruta, Yoichi Nakanishi, Isamu Okamoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The efficacy and safety of immune-checkpoint inhibitors in non-small cell lung cancer patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Herein, we describe the case of a 62-year-old man with multiple pleural tumors and carcinomatous pleurisy. High-resolution computed tomography indicated usual interstitial pneumonia, and a respiratory function test revealed a restrictive disorder and decreased diffusion capacity. He was diagnosed with lung adenocarcinoma and IPF. After failure of initial chemotherapy, he was treated with nivolumab and achieved a complete response without any sign of exacerbation of IPF. The response to nivolumab has persisted for > 1 year. This is the first report of a non-small cell lung cancer patient with IPF who has been treated with immune-checkpoint inhibitors for such a long period and achieved a sustained response.

Original languageEnglish
Pages (from-to)1519-1521
Number of pages3
JournalThoracic Cancer
Volume9
Issue number11
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Idiopathic Pulmonary Fibrosis
Non-Small Cell Lung Carcinoma
Pleurisy
Respiratory Function Tests
Neoplasms
Tomography
nivolumab
Adenocarcinoma of lung
Safety
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. / Ide, Maako; Tanaka, Kentaro; Sunami, Shunya; Asoh, Tatsuma; Maeyama, Takashige; Tsuruta, Nobuko; Nakanishi, Yoichi; Okamoto, Isamu.

In: Thoracic Cancer, Vol. 9, No. 11, 01.11.2018, p. 1519-1521.

Research output: Contribution to journalArticle

Ide, Maako ; Tanaka, Kentaro ; Sunami, Shunya ; Asoh, Tatsuma ; Maeyama, Takashige ; Tsuruta, Nobuko ; Nakanishi, Yoichi ; Okamoto, Isamu. / Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. In: Thoracic Cancer. 2018 ; Vol. 9, No. 11. pp. 1519-1521.
@article{f13acd3b187a4b25bb72c6e8ad5aa491,
title = "Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis",
abstract = "The efficacy and safety of immune-checkpoint inhibitors in non-small cell lung cancer patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Herein, we describe the case of a 62-year-old man with multiple pleural tumors and carcinomatous pleurisy. High-resolution computed tomography indicated usual interstitial pneumonia, and a respiratory function test revealed a restrictive disorder and decreased diffusion capacity. He was diagnosed with lung adenocarcinoma and IPF. After failure of initial chemotherapy, he was treated with nivolumab and achieved a complete response without any sign of exacerbation of IPF. The response to nivolumab has persisted for > 1 year. This is the first report of a non-small cell lung cancer patient with IPF who has been treated with immune-checkpoint inhibitors for such a long period and achieved a sustained response.",
author = "Maako Ide and Kentaro Tanaka and Shunya Sunami and Tatsuma Asoh and Takashige Maeyama and Nobuko Tsuruta and Yoichi Nakanishi and Isamu Okamoto",
year = "2018",
month = "11",
day = "1",
doi = "10.1111/1759-7714.12853",
language = "English",
volume = "9",
pages = "1519--1521",
journal = "Thoracic Cancer",
issn = "1759-7706",
publisher = "Blackwell Publishing Asia Pty Ltd",
number = "11",

}

TY - JOUR

T1 - Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis

AU - Ide, Maako

AU - Tanaka, Kentaro

AU - Sunami, Shunya

AU - Asoh, Tatsuma

AU - Maeyama, Takashige

AU - Tsuruta, Nobuko

AU - Nakanishi, Yoichi

AU - Okamoto, Isamu

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The efficacy and safety of immune-checkpoint inhibitors in non-small cell lung cancer patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Herein, we describe the case of a 62-year-old man with multiple pleural tumors and carcinomatous pleurisy. High-resolution computed tomography indicated usual interstitial pneumonia, and a respiratory function test revealed a restrictive disorder and decreased diffusion capacity. He was diagnosed with lung adenocarcinoma and IPF. After failure of initial chemotherapy, he was treated with nivolumab and achieved a complete response without any sign of exacerbation of IPF. The response to nivolumab has persisted for > 1 year. This is the first report of a non-small cell lung cancer patient with IPF who has been treated with immune-checkpoint inhibitors for such a long period and achieved a sustained response.

AB - The efficacy and safety of immune-checkpoint inhibitors in non-small cell lung cancer patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Herein, we describe the case of a 62-year-old man with multiple pleural tumors and carcinomatous pleurisy. High-resolution computed tomography indicated usual interstitial pneumonia, and a respiratory function test revealed a restrictive disorder and decreased diffusion capacity. He was diagnosed with lung adenocarcinoma and IPF. After failure of initial chemotherapy, he was treated with nivolumab and achieved a complete response without any sign of exacerbation of IPF. The response to nivolumab has persisted for > 1 year. This is the first report of a non-small cell lung cancer patient with IPF who has been treated with immune-checkpoint inhibitors for such a long period and achieved a sustained response.

UR - http://www.scopus.com/inward/record.url?scp=85052789668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052789668&partnerID=8YFLogxK

U2 - 10.1111/1759-7714.12853

DO - 10.1111/1759-7714.12853

M3 - Article

VL - 9

SP - 1519

EP - 1521

JO - Thoracic Cancer

JF - Thoracic Cancer

SN - 1759-7706

IS - 11

ER -